Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Two new initial public offerings (IPO) are set to go ahead in the USA, raising hopes of a thaw in what has been a long winter for biotech companies going public.
Kyverna Therapeutics has filed paperwork with the US financial regulator for its IPO, which is targeting a fundraise of around $100 million.
Another Californian firm, Alto Neuroscience, has filed for an IPO of an undisclosed size.
One should remind yourself of what happened back in September:
"Avacta shares surged on Tuesday after CEO Dr Alastair Smith said he believed Avacta are ‘on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients.”
UK biotech company Avacta Group has announced positive results from the latest cohort in its clinical trial of AVA6000, the company’s targeted chemotherapy drug".
Then remind yourself that in Avacta's case, "silence is golden", as the company has not published any negative test results.
Highly ranked directors have joined the company, the Therapeutic division will attract a tremendous amount of attention before and at the upcoming ACCR conference.
Investors taking advantage of current share price, will look very clever very soon!
Worth remembering :
Most notably the Orphan Drug Designation will give Avacta, if AVA6000 is approved for treatment of soft tissue sarcoma, seven years of market exclusivity in the US, which is a significant commercial advantage.”
+
There is also a potential tax credit of 25%
Would the above also apply to AVA3996 I wonder.
Meanwhile we have Lilly presenting at the conference later on today. One of the key topics is Radiopharma and the reason why they will avoid mega pharma deals( multi billion), but focus on specialist medicine.
Ideal license deal and partner, + ( they just acquired Point Biopharma).
So watch out for the company talking about their latest acquisition.
Expect to see a re-rating of AVCT, based on :
Harpoon Therapeutics could see interest from other parties, Oppenheimer says. Harpoon Therapeutics (NASDAQ:HARP) could see interest from other bidders after the company on Monday agreed to a $23 share sale to Merck (NYSE:MRK), according to an Oppenheimer analyst. Harpoon ticked up 0.7%.
Stock is up +100% since Merck approach.
Https://www.fiercejpmweek.com/fiercejpmweekcom/jpm-2024-speakers
Sorry if this is a repeat :
AffyXell is a clinical ready stage biotechnology company with a proprietary platform engine to develop novel cell and gene therapy (CGT). This platform is a powerhouse not only for internal pipelines but also for external collaboration. We recently signed a research collaboration agreement with one of the pioneering big pharmas in CGT, which is a testimonial of the potential strength and expandability of AffyXell’s platform technologies.
We are dedicated to developing off-the-shelf allogenic cell therapies for the treatment of transplantation rejection and immune disorders. Our technology enables the merge of two different platform technologies from our parent companies: Daewoong's Mesenchymal Stem Cell technology (DW-MSC) and Avacta's Affimer technology.
Our strategic approach is to genetically modify MSCs to express Affimers, with the aim of achieving three key objectives:
1) Significantly enhanced efficacy compared to conventional MSC therapeutics.
2) A clear understanding of the mechanism of action.
3) Consistent, reproducible, and cost-effective manufacturing.
Affimer proteins, based on Stefin A, serve as non-IgG scaffold proteins capable of acting as antagonists or agonists by binding to specific antigens, much like antibodies. We have established cell banks for both DW-MSC and AffyXell, enabling consistent, reproducible, and scalable batch production from a single cell bank.
Our lead pipeline candidate, AFX001, is designed to inhibit CD40-CD40L signaling by binding to CD40L and blocking the interaction through the secretion of an anti-CD40L antagonistic Affimer. CD40-CD40L signaling plays a pivotal role in T cell activation, T cell-mediated B cell activation/differentiation, and immune responses involving antigen-presenting cells (APCs). Inhibition of T cell and B cell activation through CD40-CD40L signaling suppression offers therapeutic potential for conditions like GvHD and various autoimmune diseases, including systemic lupus erythematosus, type 1 diabetes mellitus, multiple sclerosis, and rheumatoid arthritis.
Excitingly, we have demonstrated AFX001's outstanding efficacy compared to un-transduced MSCs using a humanized Graft versus Host Disease (GvHD) mouse model. Furthermore, AFX001 exhibits comparable efficacy to a pre-clinically verified anti-CD40L antibody.
We recently concluded a smooth pre-IND meeting with the US FDA, and we are on track to initiate patient-targeted clinical trials in the second half of this year. We are ready to manufacture GMP batch for the clinical trials with the established GMP-grade Master Cell Bank (MCB) and Working Cell Bank (WCB).
The second program, AFX002 is uniquely positioned to activate patients’ regulatory T cells to induce immune tolerance, which is a critical lacking mechanism in many autoimmune disease patients. We are in the final stage of lead cell selection, and we are excited to have the in vivo efficacy data this
Ref take over of Harpoon:
MSD’s 2023 run of pipeline-building deals looks like it could continue into this year, with reports already emerging that the company is in talks to buy Harpoon Therapeutics and its T cell engager programmes.
The rumour, first reported by Bloomberg, puts a price tag of around $700 million on Harpoon, which had a market cap of around $180 million based on its last closing share price of just over $10. The stock has however rocketed to more than $21 in pre-market trading on the back of the report.
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, will be attending the 42nd JPM Healthcare Conference held in San Francisco, California, USA, from January 8 to 11, 2024. This initiative aims to showcase GenScript's exceptional strength and development potential in the biotech sector, seeking to establish deeper interactions and connections with industry partners and investors, explore future collaboration opportunities, and further advance innovation and development in the healthcare sector.
Executives from GenScript Biotech, GenScript ProBio, and Legend Biotech will each deliver speeches during the event as per the schedule below.
Company
Speaker
Speech Time
Location
GenScript
Biotech
Sherry Shao
Rotating CEO of
GenScript Biotech
January 9,
9:00 AM PST
Marriott Marquis
Ballroom C1/C2
Legend
Biotech
Ying Huang
CEO of Legend
Biotech
January 9,
2:15 PM PST
The Westin St. Francis
California East
GenScript
ProBio
Li Chen
CEO of GenScript
ProBio
January 10,
9:30 AM PST
Marriott Marquis